



**THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, OR INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA (EXCEPT IN COMPLIANCE WITH CANADIAN SECURITIES LAWS), JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE SAME WOULD BE UNLAWFUL. FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND SHALL NOT CONSTITUTE AN OFFER TO SELL OR ISSUE OR THE SOLICITATION TO BUY, SUBSCRIBE FOR OR OTHERWISE ACQUIRE ANY ORDINARY SHARES OF BIVICTRIX THERAPEUTICS PLC (THE "COMPANY") IN ANY JURISDICTION IN WHICH ANY SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL.**

This announcement does not constitute or form part of, and should not be construed as, an offer to sell or issue, or a solicitation of any offer to buy or subscribe for, any securities, in any jurisdiction, including in or into the United States of America (including its territories and possessions, any state of the United States and the District of Columbia (the "United States" or the "US")), Australia, Canada, Japan, the Republic of South Africa (each a "Restricted Jurisdiction") or any other jurisdiction where to do so might constitute a violation or breach of any applicable law nor should it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever.

Investors should not use this announcement as the basis for any investment in the securities of the Company which should only be made on the basis of information contained in the admission document (the "Admission Document") intended to be published by BiVictriX Therapeutics plc (the "Company" and, together with its subsidiary undertakings, the "Group", "BiVictriX") in due course in connection with the proposed admission of its Ordinary Shares to trading on the AIM market ("AIM") of London Stock Exchange plc (the "London Stock Exchange"), ("Admission"). Copies of the Admission Document will, following publication, be available for inspection on the Company's website at [www.bivictrix.com](http://www.bivictrix.com).

**BiVictriX Therapeutics plc**  
("BiVictriX", the "Company" or the "Group")

#### **Intention to float on AIM**

**Alderley Park, UK, 2 August 2021:** BiVictriX Therapeutics plc, the developer of targeted cancer therapies based on its novel Bi-Cygni® approach, announces its intention to apply for admission to trading on AIM ("Admission"), a market operated by the London Stock Exchange plc. SP Angel Corporate Finance LLP ("SP Angel") is acting as Nominated Advisor and Sole Broker to the Company.

**Tiffany Thorn, Chief Executive Officer and Founder of BiVictriX Therapeutics plc, said:** *"I am thrilled to announce our intention to list on AIM, signifying a new chapter in our Company's long term development.*

*"The listing will enable us to accelerate our growth and expedite the development and delivery of our next-generation, highly selective cancer therapeutics, based on our proprietary Bi-Cygni® platform. By targeting combinations of antigens expressed primarily on cancer cells, our unique approach enables clinicians to treat patients with higher precision and potentially higher doses of medication. This promises to lead to better cancer eradication, without causing harmful side-effects to the patient. Our approach could prove to be a game-changing avenue for patients diagnosed with some of the most difficult-to-treat cancers and I look forward to progressing the Group's lead programme, BVX001, to support patients suffering from one of the most aggressive cancers, Acute Myeloid Leukaemia."*

#### **Company Highlights**

- The Company's proprietary Bi-Cygni® approach has the potential to be applied to build a diverse pipeline of first-in-class therapeutics across the wider spectrum of immunotherapeutic platforms, addressing key unmet medical needs.
- BiVictriX applies state of the art techniques to identify combinations of cancer-specific targets expressed on both solid and liquid tumours. These cancer-specific "twin antigen" fingerprints clearly differentiate between cancerous and healthy cells.
- Lead asset, BVX001, is an antibody-drug conjugate which has generated encouraging preclinical data, including potential anti-cancer activity and improved selectivity compared to a commercially available antibody-drug conjugate.
- Established collaborations with a number of academic groups including University of Liverpool and Swansea University, both of which build on the know-how in the Company's novel Bi-Cygni® approach and intellectual property.
- Intellectual property protection: BiVictriX has a growing IP and patent portfolio with broad protection already in place for its lead programme BVX001.
- Strong Board and management team: The founder and CEO is a Clinical Immunologist with years of frontline NHS and highly relevant industry experience. Following Admission, she will be supported by an experienced Non-Executive Chairman, Iain Ross, and a Board of Directors with a broad range of scientific and commercial experience from industry and leading academic institutions.
- Management team focused on building a pipeline to create shareholder value whilst rapidly bringing game-changing treatments for patients forward at a vital time.
- Admission and commencement of dealings on AIM expected to take place in mid-August 2021.

### **Fundraise and use of Proceeds**

BiVictriX is proposing to raise £7.5 million (before expenses) by way of a placing and subscription of new ordinary shares (the "**Fundraise**").

The net proceeds of the Fundraise will be used to:

- Accelerate the lead optimisation of BVX001 to reach key preclinical milestones on efficacy and safety;
- Expand BiVictriX's early-stage pipeline to include two additional candidates with preclinical proof of concept;
- Grow BiVictriX's intellectual property portfolio to add further protection around BVX001 and the additional pipeline; and
- Expand BiVictriX's internal capabilities to include providing potential avenues for platform intellectual property generation and defensibility of BiVictriX's approach.

The Company will publish an Admission Document which will be available in due course on the Company's website: [www.bivictrix.com](http://www.bivictrix.com)

### **For more information, please contact:**

#### **BiVictriX Therapeutics plc**

Tiffany Thorn, Chief Executive Officer

Email: [info@bivictrix.com](mailto:info@bivictrix.com)

#### **Consilium Strategic Communications**

Ashley Tapp, Priit Piip

Tel: +44 (0) 20 3709 5700

Email: [Bivictrix@consilium-comms.com](mailto:Bivictrix@consilium-comms.com)



**SP Angel Corporate Finance LLP (NOMAD and Broker)**

David Hignell, Caroline Rowe (Corporate Finance)

Vadim Alexandre, Rob Rees (Sales & Broking)

Tel: +44 (0) 20 3470 0470

### **Forward looking statements**

This announcement includes 'forward-looking statements' which include all statements other than statements of historical facts, including, without limitation, those regarding the Company's financial position, business strategy, plans and objectives of management for future operations, or any statements preceded by, followed by or that include the words 'targets', 'believes', 'expects', 'aims', 'intends', 'will', 'may', 'anticipates', 'would', 'could' or similar expressions or negatives thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company's control that could cause the actual results, performance or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which the Company will operate in the future. These forward-looking statements speak only as at the date of this announcement. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based unless required to do so by applicable law.

### **Important notice**

**THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN, IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY JURISDICTION IN WHICH THE SAME WOULD BE UNLAWFUL.**

The distribution of this announcement and the offering, placing and/or issue of the Company's Ordinary Shares in any jurisdictions other than the United Kingdom may be restricted by law and therefore persons into whose possession this announcement, any document or other information referred to herein comes should inform themselves about and observe any such restrictions. Any failure to comply with any such restrictions may constitute a violation of the securities laws or regulations of such jurisdictions.

This announcement should not be distributed, forwarded, transmitted or otherwise disseminated in or into the United States or any of Australia, Canada, Japan or the Republic of South Africa (collectively, the "**Restricted Jurisdictions**"). This announcement is for information purposes and does not constitute an offer to sell or issue or the solicitation of an offer to buy or subscribe for securities in the United States or any other jurisdiction. The Company's Ordinary Shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the "**Securities Act**"), or under the applicable securities laws or with any securities regulatory authority of any state or other jurisdiction of the United States, and may not be offered, sold, taken up, resold, transferred or delivered, directly or indirectly within, into or in the United States, absent registration or an applicable exemption from, or except in a transaction not subject to, the registration requirements of the Securities Act and, in each case, in compliance with any applicable securities laws of any relevant state or other jurisdiction of the United States. There will be no public offer of the Company's Ordinary Shares in the United States.

In the opinion of the directors of the Company, there is a significant risk of civil, regulatory or criminal exposure to the Company and its directors were the Company's Ordinary Shares to be offered or sold into



any of the Restricted Jurisdictions. On this basis, none of the Company's Ordinary Shares have been, or will be, registered under the relevant laws of any state, province or territory of any of the Restricted Jurisdictions. There will be no public offer of the Ordinary Shares in any of the Restricted Jurisdictions or any other jurisdiction where it would be unlawful to do so. Subject to certain limited exceptions, none of the Company's Ordinary Shares may be offered, sold, taken up, resold, transferred or delivered, directly or indirectly, in, into or within any of the Restricted Jurisdictions or to, or for the account or benefit of, any national, resident or citizen of, or any corporation, partnership or other entity created or organised under the laws of, any Restricted Jurisdiction.

This announcement is not an invitation nor is it intended to be an inducement to engage in investment activity for the purpose of section 21 of the Financial Services and Markets Act 2000 (as amended) of the United Kingdom ("**FSMA**").

To the extent that this announcement does constitute an inducement to engage in any investment activity included within this announcement and any placing of the Company's securities referred to herein if subsequently made is and will only be, directed at and is only being distributed (A) in member states of the European Economic Area to persons who are who are "qualified investors" within the meaning of Article 2(e) of Regulation (EU) 2017/1129, as amended from time to time (the "**Prospectus Regulation**"); and (B) in the United Kingdom, to persons who are "qualified investors" within the meaning of Article 2 of the UK version of the Prospectus Regulation as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 (the "**UK Prospectus Regulation**"), and who are also (i) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "**Order**"); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order; or (iii) otherwise to persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as "**relevant persons**"). This announcement must not be acted on or relied on by persons who are not relevant persons. Persons distributing this announcement must satisfy themselves that it is lawful to do so. Any investment or investment activity to which this announcement relates is available only to relevant persons and will be engaged in only with such persons. Other persons should not rely or act upon this announcement or any of its contents.

This announcement is not a prospectus for the purposes of the Prospectus Regulation or the UK Prospectus Regulation.

This announcement does not contain or constitute, or form part of, any offer or any solicitation of an offer, to sell, buy or subscribe for any shares or other securities referred to herein to any person in any jurisdiction, including any Restricted Jurisdiction or in any jurisdiction to whom or in which such offer or solicitation is unlawful. Nor shall it (or any part of it) or the fact of its dissemination form the basis of, or be relied on in connection with, or act as any inducement to enter into, any contract or commitment whatsoever.

Recipients of this announcement who intend to purchase or subscribe for Ordinary Shares in the Company following publication of the final Admission Document are reminded that any such purchase or subscription must only be made solely on the basis of the information contained in the Admission Document (and, if relevant, any supplementary admission document) relating to the Company in its final form. The information contained in this announcement is for background purposes only and does not purport to be full or complete. Any future purchase of Ordinary Shares at or about the time of Admission should be made solely on the basis of the information contained in the Admission Document. No reliance may or should be placed by any person for any purposes whatsoever on the information contained in this announcement or its accuracy, fairness or completeness.

The information in this announcement may be subject to change. The anticipated timetable for Admission, including the publication of the Admission Document and/or the date of Admission, may be influenced by a

range of circumstances such as market conditions. There is no guarantee that the Admission Document will be published or that Admission will occur. Acquiring investments to which this announcement relates may expose an investor to a significant risk of losing all or part of the amount invested. Persons considering making such an investment should consult an authorised person specialising in advising on such investments.

This announcement does not constitute a recommendation concerning Admission or the Ordinary Shares.

The value of Ordinary Shares and the income from them is not guaranteed and can fall as well as rise due to stock market and currency movements. On any sale of an investment an investor may get back less than he or she originally invested. Potential investors should consult a professional adviser as to the suitability of the Ordinary Shares for the person concerned before making any investment decision. Past performance cannot be relied upon as a guide to future performance.

SP Angel, which is authorised and regulated by the Financial Conduct Authority in the United Kingdom, is acting exclusively for the Company and no-one else in connection with Admission. SP Angel will not regard any other person as its client in relation to Admission and will not be responsible to anyone other than the Company for providing the regulatory protections afforded to its clients, nor for providing advice in relation to the contents of this announcement or any transaction, arrangement or other matter referred to herein.

Neither SP Angel, nor any of its directors, officers, employees, advisers or agents accepts any responsibility or liability whatsoever for or makes any representation or warranty, express or implied, as to the truth, accuracy or completeness of the information in this announcement (or whether any information has been omitted from the announcement) or any other information relating to the Company, its subsidiaries or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of this announcement or its contents or otherwise arising in connection therewith.

Certain figures contained in this announcement, including financial information, have been subject to rounding adjustments. Accordingly, in certain instances, the sum or percentage change of the numbers contained in this document may not conform exactly with the total figure given.